These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 16794234)

  • 1. Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer.
    Henry NL; Hayes DF
    Oncologist; 2006 Jun; 11(6):541-52. PubMed ID: 16794234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Considerations in rational use of tumor markers in breast carcinoma].
    Crombach G
    Praxis (Bern 1994); 1998 Apr; 87(17):589-94. PubMed ID: 9623326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical proteomics in breast cancer: a review.
    Gast MC; Schellens JH; Beijnen JH
    Breast Cancer Res Treat; 2009 Jul; 116(1):17-29. PubMed ID: 19082706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tumor markers in breast cancer].
    Kurebayashi J
    Gan To Kagaku Ryoho; 2004 Nov; 31(12):2077-81. PubMed ID: 15570944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer.
    Generali D; Berruti A; Brizzi MP; Campo L; Bonardi S; Wigfield S; Bersiga A; Allevi G; Milani M; Aguggini S; Gandolfi V; Dogliotti L; Bottini A; Harris AL; Fox SB
    Clin Cancer Res; 2006 Aug; 12(15):4562-8. PubMed ID: 16899602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of cytologic specimens in the evaluation of prognostic and predictive factors of breast cancer: current issues and future directions.
    Sneige N
    Diagn Cytopathol; 2004 Mar; 30(3):158-65. PubMed ID: 14986295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
    Harbeck N; Nimmrich I; Hartmann A; Ross JS; Cufer T; Grützmann R; Kristiansen G; Paradiso A; Hartmann O; Margossian A; Martens J; Schwope I; Lukas A; Müller V; Milde-Langosch K; Nährig J; Foekens J; Maier S; Schmitt M; Lesche R
    J Clin Oncol; 2008 Nov; 26(31):5036-42. PubMed ID: 18711169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Integration of new and future biomarkers in the treatment of breast cancer].
    Würtz SØ; Henriksen KL; Lykkesfeldt A; Celis J; Brünner NA
    Ugeskr Laeger; 2007 Sep; 169(36):2999-3003. PubMed ID: 17953881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical markers as predictive tools for breast cancer.
    Walker RA
    J Clin Pathol; 2008 Jun; 61(6):689-96. PubMed ID: 18037665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002.
    Di Leo A; Cardoso F; Durbecq V; Giuliani R; Mano M; Atalay G; Larsimont D; Sotiriou C; Biganzoli L; Piccart MJ
    Int J Clin Oncol; 2002 Aug; 7(4):245-53. PubMed ID: 12202978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Biomarkers, tumor markers and prognostic markers in breast cancer].
    Kurebayashi J
    Nihon Rinsho; 2006 Mar; 64(3):461-6. PubMed ID: 16529036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.
    Thussbas C; Nahrig J; Streit S; Bange J; Kriner M; Kates R; Ulm K; Kiechle M; Hoefler H; Ullrich A; Harbeck N
    J Clin Oncol; 2006 Aug; 24(23):3747-55. PubMed ID: 16822847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.
    Ross JS
    Adv Anat Pathol; 2009 Jul; 16(4):204-15. PubMed ID: 19546609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.
    Viale G; Regan MM; Mastropasqua MG; Maffini F; Maiorano E; Colleoni M; Price KN; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Gusterson BA; Castiglione-Gertsch M; Gelber RD; Goldhirsch A; Coates AS;
    J Natl Cancer Inst; 2008 Feb; 100(3):207-12. PubMed ID: 18230798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor cells in breast cancer.
    Ignatiadis M; Georgoulias V; Mavroudis D
    Curr Opin Obstet Gynecol; 2008 Feb; 20(1):55-60. PubMed ID: 18197007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy.
    Hartmann O; Spyratos F; Harbeck N; Dietrich D; Fassbender A; Schmitt M; Eppenberger-Castori S; Vuaroqueaux V; Lerebours F; Welzel K; Maier S; Plum A; Niemann S; Foekens JA; Lesche R; Martens JW
    Clin Cancer Res; 2009 Jan; 15(1):315-23. PubMed ID: 19118060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer: the search for new prognostic markers.
    Davis AR
    Br J Biomed Sci; 1996 Jun; 53(2):157-61. PubMed ID: 8757694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.